Loading…
FMC Corporation
$1.4B
Market Cap
17.9
P/E
0.87
PEG
3.6%
ROCE
-66.6%
ROE
2.00
D/E
6.9%
OPM
-69.8%
% from 52W High
12
α RS
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for FMC including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

FMC Corporation, an agricultural sciences company, develops, markets, and sells crop protection chemicals in Latin America, North America, Europe, the Middle East, Africa, and Asia. The company offers crop protection chemicals, including insecticides, herbicides, and fungicides. It also provides biologicals, crop nutrition, and seed treatment products. It markets its products through its sales organization and alliance partners, independent distributors, and sales representatives. The company was founded in 1883 and is headquartered in Philadelphia, Pennsylvania.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding FMC
View All Superinvestors →
Manager Shares Value % of Fund Period
Steve Cohen Point72 Asset Management 414.2K $7.1M 0.01% Mar 2026
Jim Simons Renaissance Technologies LLC 290.2K $5.0M 0.01% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
📊 MIXED FMC Q1 2026 beats guidance; targets $1B debt reduction, new AI growth doubles
Revenue & Profitability
Q1 2026 sales: $762M, adjusted EBITDA: $72M (above high end of guidance), adjusted loss per share: -$0.23. Full-year guidance maintained: sales $3.6B-$3.8B, EBITDA $670M-$730M, adjusted EPS $1.63-$1.89. Q2 2026 guidance: sales $850M-$900M, EBITDA $130M-$150M, adjusted EPS $0.16-$0.26.
Outlook
Management sees cautious purchasing globally due to stressed liquidity and lower grower margins. Competitive pressure is most pronounced in LATAM and Asia where generics are prevalent. However, generic pricing appears to be stabilizing. The second half outlook is positive due to volume growth from new active ingredients, direct sales in Brazil, and lower partner headwinds for Rynaxypyr.
Growth Drivers
Key growth drivers include new active ingredients (sales doubled YoY in Q1), especially Isoflex in the EU and fluindapyr in LATAM and North America; direct sales in Brazil (32% of H2 orders already in hand by end of April); and the post-patent Rynaxypyr strategy focusing on high-load formulations and differentiated mixtures. Growth is also expected from plant health and Cyazypyr.
Balance Sheet & CapEx
Free cash flow guidance for 2026 is -$65M to +$65M, including approximately $150 million in restructuring cash spending. Capital spending is expected to be modestly higher than 2025. No specific capEx number beyond that was provided.
Margins
EBITDA margin declined in Q1 due to lower price and volume, partially offset by cost favorability. Full-year EBITDA margin is expected to decline 17% at the midpoint, with most impact in the first half. Cost optimization initiatives (manufacturing shift to Asia) are expected to improve margins from 2027 onward.
Key Risks
Risks include: increased uncertainty from US tariffs and the Iran conflict (energy, transportation, petrochemical costs); potential for longer conflict affecting input costs; slower-than-expected generic adoption of CTPR; and execution risk in debt reduction and strategic alternatives. Full-year guidance assumes offsetting effects from tariffs and Iran-related costs.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-07-30
Q2 EBITDA exceeded guidance despite sales headwinds from challenging market conditions, with strong free cash flow and significant progress on debt reduction. Full-year outlook was revised downward due to persistent pricing and volume pressures, but Q4 is expected to return to growth, driven by new products and improved cost structure.
Q1 2026 Q1 2026 2026-04-30
Q1 2026 results exceeded guidance midpoints, driven by strong new active ingredient sales and cost actions, despite lower overall sales and continued price pressure from generics. Debt reduction initiatives and asset sales are progressing, with full-year guidance maintained amid market and geopolitical uncertainties.
Q4 2025 Q4 2025 2026-02-05
Q4 2025 saw sales and EBITDA decline amid intense generic competition and weak grower margins, with 2026 guidance reflecting continued headwinds but growth expected from new active ingredients. The board is exploring strategic alternatives, including a potential sale, while targeting $1 billion in debt reduction.
Q3 2025 Q3 2025 2025-10-30
Third quarter results were impacted by credit constraints and generic competition, with sales down sharply due to India-related actions. Adjusted EBITDA and EPS improved year-over-year, but full-year guidance was lowered and free cash flow remains negative. Major cost reductions, manufacturing changes, and a dividend cut are underway to address ongoing challenges.
Q2 2025 Q2 2025 2025-07-31
Q2 results exceeded guidance with 1% sales growth and 2% higher adjusted EBITDA year-over-year, driven by strong growth in new actives and cost savings. The India commercial business will be divested, with guidance now excluding India, and 2027 EBITDA targets remain intact at $1.2 billion.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.